Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Purchases $17,400.00 in Stock
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Simon N. Pimstone acquired 6,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were purchased at an average cost of $2.90 per share, for a total transaction of $17,400.00. Following the completion of the purchase, the chief executive officer now directly owns 217,847 shares of the company’s stock, valued at approximately $631,756.30. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) traded down 7.41% during mid-day trading on Monday, hitting $2.50. 240,009 shares of the stock traded hands. The company has a 50 day moving average price of $3.18 and a 200-day moving average price of $5.00. Xenon Pharmaceuticals Inc. has a one year low of $2.45 and a one year high of $9.95. The stock’s market capitalization is $45.00 million.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.03. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.38 million. Xenon Pharmaceuticals had a negative net margin of 3,489.63% and a negative return on equity of 47.53%. Equities analysts anticipate that Xenon Pharmaceuticals Inc. will post ($0.96) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/14/xenon-pharmaceuticals-inc-nasdaqxene-ceo-purchases-17400-00-in-stock.html.
Several brokerages have weighed in on XENE. Jefferies Group LLC set a $5.00 price objective on shares of Xenon Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 4th. Canaccord Genuity reaffirmed a “buy” rating and set a $5.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 27th. Finally, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $11.88.
Several large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in shares of Xenon Pharmaceuticals by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 114,200 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 18,000 shares during the period. Sabby Management LLC bought a new stake in shares of Xenon Pharmaceuticals during the first quarter valued at about $1,186,000. Endurant Capital Management LP bought a new stake in shares of Xenon Pharmaceuticals during the first quarter valued at about $1,363,000. KCG Holdings Inc. bought a new stake in shares of Xenon Pharmaceuticals during the first quarter valued at about $122,000. Finally, K2 Principal Fund L.P. raised its stake in shares of Xenon Pharmaceuticals by 104.4% in the first quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 59,747 shares during the period. 56.01% of the stock is currently owned by institutional investors.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.